SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Erkal HS, Serin M, Cakmak A. Nasopharyngeal carcinomas: analysis of patient, tumor and treatment characteristics determining outcome. Radiother Oncol. 2001; 61: 247-256.
  • 2
    Roychowdhury DF, Tseng AJr, Fu KK, Weinburg V, Weidner N. New prognostic factors in nasopharyngeal carcinoma. Tumor angiogenesis and C-erbB2 expression. Cancer. 1996; 77: 1419-1426.
  • 3
    Liu MT, Hsieh CY, Chang TH, Lin JP, Huang CC, Wang AY. Prognostic factors affecting the outcome of nasopharyngeal carcinoma. Jpn J Clin Oncol. 2003; 33: 501-508.
  • 4
    Leung TW, Tung SY, Sze WK, et al. Treatment results of 1070 patients with nasopharyngeal carcinoma: an analysis of survival and failure patterns. Head Neck. 2005; 27: 555-565.
  • 5
    Yeh SA, Tang Y, Lui CC, Huang YJ, Huang EY. Treatment outcomes and late complications of 849 patients with nasopharyngeal carcinoma treated with radiotherapy alone. Int J Radiat Oncol Biol Phys. 2005; 62: 672-679.
  • 6
    Sanguineti G, Geara FB, Garden AS, et al. Carcinoma of the nasopharynx treated by radiotherapy alone: determinants of local and regional control. Int J Radiat Oncol Biol Phys. 1997; 37: 985-996.
  • 7
    Lee AW, Sze WM, Au JS, et al. Treatment results for nasopharyngeal carcinoma in the modern era: the Hong Kong experience. Int J Radiat Oncol Biol Phys. 2005; 61: 1107-1116.
  • 8
    Chu AM, Flynn MB, Achino E, Mendoza EF, Scott RM, Jose B. Irradiation of nasopharyngeal carcinoma: correlations with treatment factors and stage. Int J Radiat Oncol Biol Phys. 1984; 10: 2241-2249.
  • 9
    Vikram B, Mishra UB, Strong EW, Manolatos S. Patterns of failure in carcinoma of the nasopharynx: I. Failure at the primary site. Int J Radiat Oncol Biol Phys. 1985; 11: 1455-1459.
  • 10
    Perez CA, Devineni VR, Marcial-Vega V, Marks JE, Simpson JR, Kucik N. Carcinoma of the nasopharynx: factors affecting prognosis. Int J Radiat Oncol Biol Phys. 1992; 23: 271-280.
  • 11
    Ma J, Mai HQ, Hong MH, et al. Is the 1997 AJCC staging system for nasopharyngeal carcinoma prognostically useful for Chinese patient populations? Int J Radiat Oncol Biol Phys. 2001; 50: 1181-1189.
  • 12
    Marks JE, Bedwinek JM, Lee F, Purdy JA, Perez CA. Dose-response analysis for nasopharyngeal carcinoma: an historical perspective. Cancer. 1982; 50: 1042-1050.
  • 13
    Le QT, Tate D, Koong A, et al. Improved local control with stereotactic radiosurgical boost in patients with nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2003; 56: 1046-1054.
  • 14
    Teo PM, Leung SF, Tung SY, et al. Dose-response relationship of nasopharyngeal carcinoma above conventional tumoricidal level: a study by the Hong Kong nasopharyngeal carcinoma study group (HKNPCSG). Radiother Oncol. 2006; 79: 27-33.
  • 15
    Luo RX, Tang QX, Guo KP, et al. Comparison of continuous and split-course radiotherapy for nasopharyngeal carcinoma—an analysis of 1446 cases with squamous cell carcinoma grade 3. Int J Radiat Oncol Biol Phys. 1994; 30: 1107-1109.
  • 16
    Kwong DL, Sham JS, Chau DT, et al. The effect of interruptions and prolonged treatment time in radiotherapy for nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 1997; 39: 703-710.
  • 17
    Lee AW, Chan DK, Fowler JF, et al. Effect of time, dose and fractionation on local control of nasopharyngeal carcinoma. Radiother Oncol. 1995; 36: 24-31.
  • 18
    Tate DJ, Adler JR, Chang SD, et al. Stereotactic radiosurgical boost following radiotherapy in primary nasopharyngeal carcinoma: impact on local control. Int J Radiat Oncol Biol Phys. 1999; 45: 915-921.
  • 19
    Levendag PC, Lagerwaard FJ, de Pan C, et al. High-dose, high-precision treatment options for boosting cancer of the nasopharynx. Radiother Oncol. 2002; 63: 67-74.
  • 20
    Lee AW, Sze WM, Yau TK, et al. Retrospective analysis on treating nasopharyngeal carcinoma with accelerated fractionation (6 fractions per week) in comparison with conventional fractionation (5 fractions per week): Report on 3-year tumor control and normal tissue toxicity. Radiother Oncol. 2001; 58: 121-130.
  • 21
    Wolden SL, Zelefsky MJ, Hunt MA, et al. Failure of a 3D conformal boost to improve radiotherapy for nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2001; 49: 1229-1234.
  • 22
    Jen YM, Lin YS, Su WF, et al. Dose escalation using twice-daily radiotherapy for nasopharyngeal carcinoma: does heavier dosing result in a happier ending? Int J Radiat Oncol Biol Phys. 2002; 54: 14-22.
  • 23
    Teo PM, Leung SF, Chan AT, et al. Final report of a randomized trial on altered-fractionated radiotherapy in nasopharyngeal carcinoma prematurely terminated by significant increase in neurologic complications. Int J Radiat Oncol Biol Phys. 2000; 48: 1311-1322.
  • 24
    Lu H, Yao M. The current status of intensity-modulated radiation therapy in the treatment of nasopharyngeal carcinoma. Cancer Treat Rev. 2008; 34: 27-36.
  • 25
    Xia P, Fu KK, Wong GW, Akazawa C, Verhey LJ. Comparison of treatment plans involving intensity-modulated radiotherapy for nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2000; 48: 329-337.
  • 26
    Cheng JC, Chao KS, Low D. Comparison of intensity modulated radiation therapy (IMRT) treatment techniques for nasopharyngeal carcinoma. Int J Cancer. 2001; 96: 126-131.
  • 27
    Hunt MA, Zelefsky MJ, Wolden S, et al. Treatment planning and delivery of intensity-modulated radiation therapy for primary nasopharynx cancer. Int J Radiat Oncol Biol Phys. 2001; 49: 623-632.
  • 28
    Kam MK, Chau RM, Suen J, Choi PH, Teo PM. Intensity-modulated radiotherapy in nasopharyngeal carcinoma: dosimetric advantage over conventional plans and feasibility of dose escalation. Int J Radiat Oncol Biol Phys. 2003; 56: 145-157.
  • 29
    Butler EB, Teh BS, Grant WHIII, et al. Smart (simultaneous modulated accelerated radiation therapy) boost: a new accelerated fractionation schedule for the treatment of head and neck cancer with intensity modulated radiotherapy. Int J Radiat Oncol Biol Phys. 1999; 45: 21-32.
  • 30
    Teh BS, Woo SY, Butler EB. Intensity modulated radiation therapy (IMRT): a new promising technology in radiation oncology. Oncologist. 1999; 4: 433-442.
  • 31
    Lee SW, Back GM, Yi BY, et al. Preliminary results of a phase I/II study of simultaneous modulated accelerated radiotherapy for nondisseminated nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2006; 65: 152-160.
  • 32
    Kim K, Wu HG, Kim HJ, et al. Intensity-modulated radiation therapy with simultaneous integrated boost technique following neoadjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma. Head Neck. 2009; 31: 1121-1128.
  • 33
    Chen SW, Yang SN, Liang JA, Shiau AC, Lin FJ. Comparative dosimetric study of 2 strategies of intensity-modulated radiotherapy in nasopharyngeal cancer. Med Dosim. 2005; 30: 219-227.
  • 34
    Koom WS, Kim TH, Shin KH, et al. SMART (simultaneous modulated accelerated radiotherapy) for locally advanced nasopharyngeal carcinomas. Head Neck. 2008; 30: 159-169.
  • 35
    Kwong DL, Sham JS, Leung LH, et al. Preliminary results of radiation dose escalation for locally advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2006; 64: 374-381.
  • 36
    Wolden SL, Chen WC, Pfister DG, Kraus DH, Berry SL, Zelefsky MJ. Intensity-modulated radiation therapy (IMRT) for nasopharynx cancer: update of the Memorial Sloan-Kettering experience. Int J Radiat Oncol Biol Phys. 2006; 64: 57-62.
  • 37
    Lin S, Pan J, Han L, Zhang X, Liao X, Lu JJ. Nasopharyngeal carcinoma treated with reduced-volume intensity-modulated radiation therapy: report on the 3-year outcome of a prospective series. Int J Radiat Oncol Biol Phys. 2009; 75: 1071-1078.
  • 38
    Fleming ID, Cooper JS, Henson DE, et al. AJCC Cancer Staging Manual. 5th ed. Philadelphia, PA: Lippincott-Raven; 1997.
  • 39
    International Commission on Radiation Units and Measurements. Report 50: Prescribing, recording, and reporting photon beam therapy. Bethesda, MD: ICRU; 1993.
  • 40
    International Commission on Radiation Units and Measurements. Report 62: Prescribing, recording and reporting photon beam therapy (supplement to ICRU report 50). Bethesda, MD: ICRU; 1999.
  • 41
    Al-Sarraf M, LeBlanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase 3 randomized Intergroup study 0099. J Clin Oncol. 1998; 16: 1310-1317.
  • 42
    Orton CG. Recent developments in time-time modeling. Australas Phys Eng Sci Med. 1991; 14: 57-64.
  • 43
    Barendsen GW. Dose rate and isoeffect relationships for normal tissue responses. Int J Radiat Oncol Biol Phys. 1982; 8: 1981-1997.
  • 44
    Dale EG. The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy. Br J Radiol. 1985; 58: 515-528.
  • 45
    Fowler JF. Brief summary of radiobiological principles in fractionated radiotherapy. Semin Radiat Oncol. 1992; 2: 16-21.
  • 46
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc. 1958; 53: 457-481.
  • 47
    Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995; 13: 1341-1346.
  • 48
    Fleming ID, Cooper JS, Henson DE. American Joint Committee on Cancer: AJCC Cancer Staging Manual. New York, NY: Springer-Verlag; 2002.
  • 49
    Sobin LH, Wittekind CH. International Union Against Cancer (UICC): TNM Classification of Malignant Tumors. New York, NY: Wiley-Liss; 2002.
  • 50
    Lee AW, Tung SY, Chua DT, et al. Randomized trial of radiotherapy plus concurrent-adjuvant chemotherapy versus radiotherapy alone for regionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst. 2010; 102: 1188-1198.
  • 51
    Palazzi M, Guzzo M, Tomatis S, et al. Improved outcome of nasopharyngeal carcinoma treated with conventional radiotherapy. Int J Radiat Oncol Biol Phys. 2004; 60: 1451-1458.
  • 52
    Wu S, Xie C, Jin X, et al. Simultaneous modulated accelerated radiation therapy in the treatment of nasopharyngeal carcinoma: a local center';s experience. Int J Radiat Oncol Biol Phys. 2006; 66(4 suppl): S44-S46.
  • 53
    Lee N, Harris J, Garden AS, et al. Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: Radiation Therapy Oncology Group phase II trial 0225. J Clin Oncol. 2009; 27: 3684-3690.
  • 54
    Tham IW, Hee SW, Yeo RM, et al. Treatment of nasopharyngeal carcinoma using intensity-modulated radiotherapy—the National Cancer Centre Singapore experience. Int J Radiat Oncol Biol Phys. 2009; 75: 1481-1486.
  • 55
    Kam MK, TeoPML, Chau RMC, et al. Treatment of nasopharyngeal carcinoma with intensity-modulated radiotherapy: the Hong Kong experience. Int J Radiat Oncol Biol Phys. 2004; 60: 1440-1450.
  • 56
    Lee N, Xia P, Quivey JM, et al. Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. Int J Radiat Oncol Biol Phys. 2002; 53: 12-22.
  • 57
    Langendijk JA, Leemans CR, Buter J, Berkhof J, Slotman BJ. The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma: a meta-analysis of the published literature. J Clin Oncol. 2004; 22: 4604-4612.
  • 58
    Lee AW, Tung SY, Chan AT, et al. Preliminary results of a randomized study (NPC-9902 Trial) on therapeutic gain by concurrent chemotherapy and/or accelerated fractionation for locally advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2006; 66: 142-151.
  • 59
    Chitapanarux I, Lorvidhaya V, Kamnerdsupaphon P, et al. Chemoradiation comparing cisplatin versus carboplatin in locally advanced nasopharyngeal cancer: randomized, noninferiority, open trial. Eur J Cancer. 2007; 43: 1399-1406.
  • 60
    Hui EP, Ma BB, Leung SF, et al. Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. J Clin Oncol. 2009; 27: 242-249.